Issued by: Ministry of Commerce, National Health Commission, National Medical Products Administration
Issue No.: Shangzihan [2024] No. 568
Release Date: September 7, 2024
Links: https://www.gov.cn/zhengce/zhengceku/202409/content_6973072.htm

The content of the Notice are as follows:
1. Foreign-invested enterprises are allowed to engage in technology development and technology application in human stem cell, gene diagnostic and therapeutic for product registration for marketing and production in four FTZs/FTPs (Beijing, Shanghai, Guangzhou and Hainan);

2. It is proposed to allow the establishment of wholly foreign-owned hospitals (except for Chinese medicine, and excluding mergers and acquisitions of public hospitals) in Beijing, Tianjin, Shanghai, Nanjing, Suzhou, Fuzhou, Guangzhou, Shenzhen and Hainan Island. Specific conditions, requirements and procedures for the establishment of wholly foreign-owned hospitals will be announced separately.